Charles River-WuXi PharmaTech Deal Transforms China's CRO Landscape
This article was originally published in PharmAsia News
Executive Summary
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
You may also be interested in...
China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference
BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19
China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference
BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19
PPD Opens Vaccine Clinical Research Center In Taizhou: One Step Closer To Its Goal To Become China's Number One Service Provider
SHANGHAI - PPD has been touting the opening of its new Vaccines and Biologics Center of Excellence in Wayne, Pennsylvania, and now the company is pushing its vaccine expansion into China with the launch of a vaccine clinical research center in Taizhou China Medical City